• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

98.37 -0.60 (-0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
April 28, 2026
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
April 16, 2026
Via ACCESS Newswire
News headline image
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 28, 2026
Via ACCESS Newswire
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
March 23, 2026
In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of... 
Via MarketMinute
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
March 21, 2026
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
March 21, 2026
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
March 20, 2026
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 18, 2026
Via ACCESS Newswire
News headline image
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
March 02, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
Via ACCESS Newswire
News headline image
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
Via ACCESS Newswire
News headline image
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
February 25, 2026
This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
February 24, 2026
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗
February 16, 2026
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗
February 01, 2026
The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
January 15, 2026
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
January 07, 2026
Via ACCESS Newswire
News headline image
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
January 05, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist (PTGX) Earnings Call Transcript ↗
November 27, 2025
Protagonist (PTGX) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
November 27, 2025
Via ACCESS Newswire
News headline image
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 06, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
November 03, 2025
Via ACCESS Newswire
News headline image
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
October 28, 2025
 
Via Benzinga
News headline image
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
October 27, 2025
Via ACCESS Newswire
News headline image
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗
October 23, 2025
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million 
Via The Motley Fool
Topics Energy
News headline image
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗
October 23, 2025
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million 
Via The Motley Fool
News headline image
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗
October 21, 2025
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million 
Via The Motley Fool
Topics Regulatory Compliance
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
October 20, 2025
Via AB Newswire
News headline image
2 Top Dividend Kings Every Income Investor Should Own ↗
October 20, 2025
These companies pay durable and steadily rising dividends. 
Via The Motley Fool
Topics Bonds
News headline image
Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗
October 18, 2025
Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap